Group 1 - Company Tonghe Pharmaceutical recently announced the receipt of three invention patent certificates from the National Intellectual Property Administration of China [1] - The patents include methods for the preparation of key intermediates for Resmetirom, as well as methods and applications for pyrazine compounds and their nitro derivatives, and the preparation method for Upatacitinib intermediates [1]

Group 1 - The core point of the article is that Tonghua Golden Horse has completed the comprehensive review of its new chemical drug, Amber Tetrahydroaminoacridine Tablets, and is now in the final review stage [2] - The company has provided all required professional research materials as part of the review process [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]

Core Viewpoint - Rundu Co., Ltd. has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating the product's approval for the treatment of primary hypertension [1] Company Summary - Rundu Co., Ltd. is now authorized to market Candesartan Cilexetil Tablets, which are specifically indicated for primary hypertension [1]

2月6日，东方金诚国际信用评估有限公司(以下简称"东方金诚")发布《东方金诚国际信用评估有限公司 关于博瑞生物医药(苏州)股份有限公司2025年度业绩下滑的关注公告》(以下简称《公告》)称，上述事 项发生后，东方金诚通过向公司邮件询问、查询公开资料等方式了解到，公司业绩下滑主要系：受流感 趋势变化、竞争格局变化、客户阶段性商业需求波动等影响，使得当期营业收入及产品毛利额减少，以 及在建工程陆续完工转固带来计提折旧增加，同时创新药等研发投入加大使得研发费用等期间费用同比 有所增加。 1月31日，博瑞医药发布的业绩预告显示，预计2025年年度实现归属于母公司所有者的净利润4130万元 到6190万元，同比减少67.28%到78.17%。预计2025年年度实现归属于母公司所有者的扣除非经常性损 益的净利润430万元到2490万元，同比减少86.21%到97.62%。 此前，东方金诚受托对博瑞医药及其发行的"2021年博瑞生物医药(苏州)股份有限公司向不特定对象发 行可转换公司债券"(以下简称"博瑞转债")进行了信用评级。2025年5月27日，东方金诚对博瑞医药主体 及"博瑞转债"进行了定期跟踪评级，维持博瑞医药主体 ...

来源：新浪证券-红岸工作室 2月9日，海普瑞涨0.82%，成交额5261.62万元，换手率0.34%，总市值180.62亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 该股筹码平均交易成本为11.66元，近期筹码减仓，但减仓程度减缓；目前股价靠近支撑位12.23，注意 支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建 ...

Core Insights - The main market saw a net inflow of 26.126 billion yuan as of February 9, indicating a positive trend in overall market sentiment [1]. Sector Analysis - The top ten sectors with the largest net outflows of funds were as follows: - **Beverage Industry**: Experienced a net outflow of 1.523 billion yuan, with Huangtai Liquor being the largest contributor to this outflow [2]. - **Precious Metals**: Saw a net outflow of 1.278 billion yuan, primarily driven by Shandong Gold [2]. - **General Equipment**: Had a net outflow of 0.985 billion yuan, with Yingliu Co. being the main affected company [2]. - **Chemical Pharmaceuticals**: Experienced a net outflow of 0.693 billion yuan, with Xinhengcheng as the largest contributor [2]. - **Traditional Chinese Medicine**: Faced a net outflow of 0.635 billion yuan, with Guangdong Wannianqing leading the outflow [2]. - **Biological Products**: Saw a net outflow of 0.540 billion yuan, with Wanze Co. being the most impacted [2]. - **Oil Industry**: Experienced a net outflow of 0.483 billion yuan, with Heshun Oil being the largest contributor [3]. - **Agriculture, Animal Husbandry, and Fishery**: Had a net outflow of 0.422 billion yuan, with Xue Rong Biological being the main affected company [3]. - **Commercial Retail**: Faced a net outflow of 0.418 billion yuan, with Wangfujing leading the outflow [3]. - **Telecommunication Services**: Experienced a net outflow of 0.375 billion yuan, with Erli San being the largest contributor [3].

Core Insights - Longhua Technology (联化科技) is positioned as a leading player in the agricultural and pharmaceutical CDMO sectors, with significant achievements in small nucleic acid CDMO and potential in functional chemicals [1][2] Business Overview - Longhua Technology has established a collaborative development framework across four core industrial segments: agricultural protection, pharmaceuticals, functional chemicals, and equipment & engineering services [2] - The agricultural protection segment generated revenue of 1.702 billion yuan in the first half of 2025, with a gross margin increase of 9.48% year-on-year [2] - The pharmaceutical segment, focusing on APIs and intermediates, achieved revenue of 1.018 billion yuan in the first half of 2025, reflecting a year-on-year growth of 42.80% [2] Small Nucleic Acid CDMO - The company is leveraging small nucleic acid CDMO to tap into new growth opportunities, with advantages over traditional small molecule and antibody drugs, including broader target selection and higher success rates [3] - Since 2022, the market for small nucleic acid drugs has seen significant activity, with 32 transactions totaling 29.022 billion USD in 2025, indicating strong commercial value [3] - Longhua Technology has developed scalable production processes for modified nucleotides and has established a high-efficiency delivery system for nucleic acid drugs, enhancing its competitive edge [3] Functional Chemicals and Market Potential - The functional chemicals segment reported revenue of 0.265 billion yuan in the first half of 2025, marking a year-on-year doubling [4] - The company is focusing on lithium battery materials, including lithium hexafluorophosphate and LiFSI, with ongoing product development in various testing phases [4] - The National Development and Reform Commission's new storage action plan aims for over 1.8 million kilowatts by 2027, which is expected to drive significant market demand in the energy storage sector [4] Financial Performance - For the first three quarters of 2025, Longhua Technology reported total revenue of 4.718 billion yuan, an increase of 8.25% year-on-year, and a net profit of 316 million yuan, surging by 871.65% [1] - The projected net profit for 2025 is estimated to be between 350 million and 420 million yuan, representing a year-on-year growth of 239.35% to 307.22% [4]

Core Viewpoint - Company *ST Shuangcheng (002693.SZ)* has announced that its 2025 annual report is scheduled for disclosure on April 29, 2026, and it is committed to fulfilling its information disclosure obligations in accordance with relevant laws and regulations [1]. Group 1 - Company has received inquiries from investors regarding the feasibility and plans for early disclosure of the 2025 annual report [3]. - Investors expressed optimism about the company's forecasted profitability for the 2025 fiscal year, indicating potential for the company to remove its "ST" designation [3]. - Questions were raised about whether the company would expedite the process of removing the "ST" designation to stabilize market expectations and reduce investor anxiety [3].

Group 1 - Company SciGen Pte. Ltd., a wholly-owned subsidiary of Yifan Pharmaceutical, has received approval from the Health Sciences Authority (HSA) of Singapore for the marketing registration of its pharmaceutical product, Norepinephrine SciGen, a concentrated solution for injection [1] - The product is indicated for the management of severe acute hypotension in adults and was approved domestically in March 2023, with the registration application submitted to HSA in December 2023 [1] - The approval supports the company's strategy for "full-category, multi-region" international expansion, with domestic production lines receiving international certification [1] Group 2 - The approval is not expected to have a significant short-term impact on the company's operating performance, but successful commercialization in the future could yield positive effects [1] - The operational situation may be influenced by overseas policies and exchange rate fluctuations, indicating some uncertainty for investors [1]

Group 1 - Company Saisir signed a cooperation agreement with the Shapingba District Government of Chongqing, establishing a new company funded by the separation of existing assets related to blue electric vehicles [1] - The new company will have a shareholding structure where the SPV holds approximately 33.5%, other investors hold about 18.5%, and the company and its designated entities hold around 32% [1] - The new company's board will consist of 5 members, with the company appointing 1 member [1] Group 2 - Yunlu Co., Ltd. announced that the detention measures against its Chairman and General Manager, Li Xiaoyu, have been lifted, allowing him to resume his duties [2] - Lin Yang Energy's controlling shareholder plans to increase its stake in the company by investing between 50 million and 100 million yuan within the next 12 months [3] - Zhongfu Shenying's controlling shareholder plans to reduce its stake by up to 3%, amounting to a maximum of 27 million shares [4] Group 3 - Anlu Technology's shareholders, including several investment funds, plan to collectively reduce their stake by up to 4% [5] - Jinfeng Technology is in the planning stage of a share acquisition, with its controlling shareholder intending to transfer 6% of the company's shares [6] - Shenjian Co., Ltd. reported that its revenue from the commercial aerospace sector is less than 1% of its total revenue, indicating limited contribution from this segment [7] Group 4 - Guolian Minsheng plans to increase its investment in Minsheng Securities by 200 million yuan, with the funds sourced from a specific stock issuance [8] - Zhongsheng Pharmaceutical's subsidiary has reported positive results from two Phase III clinical trials for its innovative drug, indicating effective treatment for influenza in children and adolescents [9] - Mingguan New Materials has decided to terminate its investment in a solar backplane and functional film production project due to industry overcapacity and declining profitability [10] Group 5 - Huading Co., Ltd.'s controlling shareholder plans to publicly solicit buyers for a 6% stake in the company [11] - Tiancheng Auto Control's subsidiary has received a notification to supply passenger car seats for a major automotive client, with a project lifecycle value of 2.3 billion yuan [12] - Shanshan Co., Ltd. signed a restructuring investment agreement that may lead to a change in its controlling shareholder to Anhui State-owned Assets Supervision and Administration Commission [13] Group 6 - Sichuan Changhong intends to transfer 58.33% of its subsidiary's equity to its controlling shareholder for 33.1245 million yuan, as the subsidiary's business has ceased operations [14] - Ruili Kemi is planning to acquire a 16% stake in its subsidiary, with the stock being suspended from trading [15] - Yongtai Technology is also planning to purchase a 25% stake in Yongtai High-tech from Ningde Times, with its stock suspended from trading as well [16][17]